Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol-- drastically and in a wide variety of different patient populations-- data from one trial offers the first suggestion that the drugs may in fact improve cardiovascular outcomes. But the analysis, the authors cautioned, is a post-hoc [...]